在结直肠癌中准肝素会触发TNF-依赖的-加斯德明E驱动的免疫细胞死亡反应
Antonio Di Grazia1, Eleonora Franzè1, Rachele Frascatani1
1Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy.
Experimental hematology & oncology
|September 28, 2024
概括
在结直肠癌 (CRC) 细胞中向肝素可以提高抗瘤免疫力. 肝素缺乏会促进T细胞的反应,提高免疫疗法的有效性,导致瘤生长的减少.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 结肠直肠癌 (CRC) 细胞与瘤微环境 (TME) 相互作用,以逃避免疫监测.
- 肝素是一种调节免疫细胞功能的,在CRC中过度产生.
- 这项研究研究了西丁在CRC中调节抗瘤免疫力的作用.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K